Development of a modified gp130 ligand to treat obesity-induced insulin resistance [ 2012 - 2014 ]

Also known as: A new treatment for obesity-induced insulin resistance

Research Grant

[Cite as]

Researchers: Prof Mark Febbraio (Principal investigator) ,  Dr Tim Adams Prof Michael Cowley

Brief description IC7 is a mixture of two naturally occurring proteins, CNTF and IL-6. These gp130 receptor ligands have been shown to have positive metabolic effects in humans, but individually they are not suitable for therapeutic use. IC7, the novel molecule this technology is based upon, is a combination of CNTF and IL-6 in a specific design to avoid the negative effects. Preliminary results suggest that IC7 has positive metabolic effects but further development is required to increase its effectiveness in treating insulin resistance and type 2 diabetes.

Funding Amount $AUD 438,533.45

Funding Scheme Development Grants

Notes Development Grant

Viewed: [[ro.stat.viewed]]